<DOC>
	<DOCNO>NCT00661102</DOCNO>
	<brief_summary>This 3 arm study compare prophylactic effect topical corticosteroid , Bepantol placebo hand-foot syndrome patient receive Xeloda treatment metastatic breast cancer , metastatic colorectal cancer adjuvant treatment colorectal cancer . Patients receive oral Xeloda least 5 day randomize receive prophylactic treatment either placebo , topical corticosteroid Bepantol . The anticipated time study treatment disease progression development hand-foot syndrome , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Prophylactic Treatment Hand-Foot Syndrome Patients Treated With Oral Xeloda ( Capecitabine ) .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hand-Foot Syndrome</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; breast cancer colorectal cancer patient ; treat oral Xeloda &lt; =5 day ; lack handfoot syndrome ( palmarplantar erythrodysesthesia ) . existence clinical symptom suggest handfoot syndrome ; use doxorubicin , 5FU and/or cytarabine last 3 month ; diabetes mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>